100 results about "Elongation factor" patented technology

Methods, compositions, kits, and apparatus are provided wherein the aminoacyl-tRNA synthetase system is used to analyze amino acids. The method allows very small devices for quantitative or semi-quantitative analysis of the amino acids in samples or in sequential or complete proteolytic digestions. The methods can be readily applied to the detection and/or quantitation of one or more primary amino acids by using cognate aminoacyl-tRNA synthetase and cognate tRNA. The basis of the method is that each of the 20 synthetases and/or a tRNA specific for a different amino acid is separated spatially or differentially labeled. The reactions catalyzed by all 20 synthetases may be monitored simultaneously, or nearly simultaneously, or in parallel. Each separately positioned synthetase or tRNA will signal its cognate amino acid. The synthetase reactions can be monitored using continuous spectroscopic assays. Alternatively, since elongation factor Tu:GTP (EF-Tu:GTP) specifically binds all AA-tRNAs, the aminoacylation reactions catalyzed by the synthetases can be monitored using ligand assays. Microarrays and microsensors for amino acid analysis are provided. Additionally, amino acid analysis devices are integrated with protease digestions to produce miniaturized enzymatic sequenators capable of generating either N- or C-terminal sequence and composition data for a protein or peptide. The possibility of parallel processing of many samples in an automated manner is discussed.

A dermal patch having comprising at least two layers wherein at least one layer is a polymer matrix system having an active agent admixed therein. At least one of the layers includes a water-dispersible or water-dissipatable polymer. The dermal patch has an elongation factor of at least 50%.

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

A real-time assay coupled with a non-invasive tissue sampling was developed for the detection and quantification of fish viruses. As a proof of principles, data were presented for the detection and quantification of infectious hypodermal necrosis virus (IHNV) in trout. The primers were designed for IHNV nucleocapsid (N), and surface glycoprotein (G) genes, and trout &bgr;-actin and elongation factor-l&agr; (EF-I &agr;) were used as internal control for the assay. The reaction conditions for the real-time RT-PCR were optimized using cDNA derived from IHNV-infected Epithelioma papulosum cyprinid (EPC) cells. Using both N- and G-gene primers, IHNV was successfully detected in liver, kidney, spleen, adipose tissue and pectoral fin samples of laboratory-challenged and wild samples. The dissociation curves with a single melting peak at expected temperature (85° C. for the N-gene and 86.5° C. for the G-gene) confirmed the specificity of the N- and G-gene amplicons. The IHNV N- and the G-gene expression levels in different tissues of laboratory challenged samples were in the order of spleen, liver, kidney, adipose tissue and pectoral fin, however in the field-collected samples the order of gene expression was liver, kidney, pectoral fin, adipose tissue, and spleen. The N- and G-gene expressions in spleen were found to be dramatically lower in the field-collected samples compared to the laboratory-challenged samples indicating a potential difference in the IHNV replication in the laboratory as opposed to field conditions. The real-time PCR assay was found to be rapid, highly sensitive, and reproducible. Based upon the ability to detect the virus in pectoral fins a non-invasive detection method for IHNV and other fish viruses is developed. Such a non-invasive tissue sampling coupled with real-time PCR assay is very valuable for large-scale virus screening of fish in aquaculture facilities as well as for epidemiological studies.

Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein.

The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers.

The present invention relates to a highly efficient eukaryotic expression vector containing an exogenous transcription regulatory element which comprises a promoter/enhancer and the nucleotide sequence upstream of the translation initiation codon derived from human cytomegalovirus (HCMV) immediately early (IE) gene or human elongation factor 1alpha (EF1alpha) gene.

Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein.

Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein.

The invention belongs to the technical field of photodynamic gene therapy, particularly relating to a photosensitizer binding protein and polypeptide and application thereof. In the invention, the photosensitizer binding protein is screened from a human liver cDNA (complementary Deoxyribonucleic Acid) phage display library. The binding protein is a human eukaryotic translation elongation factor (eEF1A1) protein and a protein molecule which is 70 to 80 percent similar to the protein in protein structure; the photosensitizer binding polypeptide is eEF1A1 C terminal 25aa and polypeptide which is70 to 80 percent similar to the 25aa in amino acid sequence. The photosensitizer binding protein can be bound with a porphyrin type photosensitizer in vitro and has an effect of enriching the porphyrin type photosensitizer in vivo; photosensitizer binding protein genes are transfected to various mammalian cells through adenoviruses, slow viruses or other modes; and a better photodynamic therapy effect is produced after artificial adjustment and control over inducible expression. In addition, the photosensitizer binding protein and polypeptide (PSP) provide a valuable reference for developing a photosensitizer prodrug and designing the specifically targeted photosensitizer.

A purified Leishmania infantum polypeptide comprising at least 10 consecutive amino acids of a protein is provided. The protein is mitochondrial integral ADP/ATP carrier protein, NADH-cytochrome b5 reductase, mitochondrial carrier protein, guanine nucleotide binding protein beta subunit (LACK), aldehyde reductase, ubiquinol-cytochrome-c reductase Rieske iron-sulfur protein, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 36.4 kDa, truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 34.5 kDa, or truncated elongation factor 1-alpha having a molecular weight as determined by SDS-PAGE of 30.6 kDa. Methods for using the polypeptides for diagnosing MVL are disclosed.

The invention discloses a brown planthopper protein translation elongation factor NlEF1gamma, an encoded protein, synthesized dsRNA, and an application thereof in controlling brown planthopper pest diseases. The gene performs an important function in maintaining the normal growth and development processes of brown planthoppers. When the function is inhibited, brown planthopper nymph growth is slower, brown planthopper nymph size is smaller, and brown planthopper nymph dies because it couldn't develop into adult. When the function of the gene in a brown planthopper female adult is inhibited, its ovaries stop developing and it couldn't spawn normally. According to the invention, brown planthoppers are injected and fed with the dsRNA of the gene fragment. With both means the brown planthopper death rates reach 70% and brown planthopper spawning amounts are 0. Sequence and data bases are provided for establishing novel strategies for controlling pests with an RNA interference technology. The application has significant lethal and ovarian development inhibition effects against brown planthoppers. Therefore, the gene can be sued as an effective target for controlling the pest with an RNAi technology.

The invention discloses three reference genes suitable for qPCR of octopuses and the application of the genes in real-time fluorescence quantitative PCR. The beneficial effect is that the genes can bestably expressed under different environments and experimental conditions without being affected by any internal and external factors; by using elongation factor-1 alpha, 18s and ubiquitin elongationfactor-1 alpha as the reference genes to be applied to real-time fluorescence quantitative PCR, the requirement for real-time fluorescence quantitative PCR detection of the genetic transcription expression level of the octopuses can be met, and the stability and reliability of gene expression analysis and study of the octopuses are improved.

The invention discloses a multiplex RT-PCR method for simultaneously detecting four corn viruses, and belongs to the technical field of plant virus detection. According to the method disclosed by theinvention, corn elongation factor 1 alpha (Elongation factor 1 alpha, EF 1 alpha) gene is used as a reference gene; on the basis of optimizing the annealing temperature and the primer concentration ofa multiplex PCR detection system, a multiplex RT-PCR detection method for simultaneously detecting four kinds of maize viruses MCMV, SCMV, MaYMV and MATV is established. The multiplex PCR detection system disclosed by the invention is a detection method which is simple, rapid, economical and low in time consumption, and can be used for simultaneously detecting four viruses (MCMV, SCMV, MaYMV andMATV) of corn; the method can be widely applied to agriculture to diagnose the four viruses on the corn in advance, and has very important significance in controlling the occurrence of diseases and increasing economic benefits.

The invention provides a eukaryotic expression vector capable of selecting high expression clones conveniently and high efficiently. The eukaryotic expression vector is obtained via structure modification by taking pBudCE4.1 carrier as a basic carrier; peptide chain elongation factor gene promoter (P) on the basic carrier, and multiple cloning sites on the downstream of the peptide chain elongation factor gene promoter (P) are replaced by an expression element composed of attenuated SV40 promoter and dihydrofolate reductase gene on the downstream of the attenuated SV40 promoter; multiple cloning sites on the downstream of cytomegalovirus early promoter (P) of the basic carrier are replaced by new multiple cloning sites.

The invention discloses a reference gene for barley gene expression researches as well as application of the reference gene. The reference gene is a gene segment of a ubiquitin-conjugating enzyme E2, an elongation factor EF2 and/or a tubulin beta-tubulin 6, wherein a nucleotide sequence of the gene segment of the ubiquitin-conjugating enzyme E2 is shown as SEQ ID NO.1, a nucleotide sequence of the gene segment of the elongation factor EF2 is shown as SEQ ID NO.2, and a nucleotide sequence of the gene segment of the tubulin beta-tubulin 6 is shown as SEQ ID NO.3. According to the reference gene, the detection accuracy of a barley related gene (such as low nitrogen stress and drought stress) expression can be improved, and the reference gene is large in expression quantity and stable in expression, and has a Ct value of 20 to 30.

Disclosed are a Pichia pastoris-derived translation elongation factor (TEF) promoter, a recombinant expression vector carrying the promoter and a heterologous protein encoding base sequence operably linked to the promoter, and a host cell transfected or transformed with the recombinant expression vector. Also, a method is provided for producing a heterologous protein. The method comprises culturing the host cell to express the Pichia pastoris-derived TEF promoter and isolating the promoter from the culture. The TEF promoter can be utilized for the mass production of heterologous proteins without the need for inducers.

There is described antifungal combination use of known antifungal agents such as the azoles or polyenes in combination with a lipopeptide compound antifungal agent. More particularly, the invention relates to antifungal combination use of azols such as fluconazole voriconazole, itraconazole, ketoconazole, miconazole, ER 30346 and SCH 56592; polyenes such as amphotericin B, nystatin, liposomal and lipid forms thereof such as Abelcet, AmBisome and Amphocil; purine or pyrimidine nucleotide inhibitors such as flucytosine; or polyoxins such as nikkomycins, in particular nikkomycin Z or nikkomycin X; other chitin inhibitors; elongation factor inhibitors such as sordarin and analogs thereof; mannan inhibitors such as predamycin, bactericidal/permeability-inducing (BPI) protein products such as XMP.97 or XMP.127; or complex carbohydrate antifungal agents such as CAN-296; with a lipopeptide compound (I) as described herein.

Provided is a method for producing a polyisoprenoid, which can increase natural rubber production by enhancing the rubber synthesis activity of rubber particles. The present invention provides methods for producing a polyisoprenoid using a gene coding for a cis-prenyltransferase (CPT) family protein, a gene coding for a Nogo-B receptor (NgBR) family protein and a gene coding for a rubber elongation factor (REF) family protein, specifically a method for producing a polyisoprenoid in vitro using rubber particles bound to proteins coded for by these genes, and a method for producing a polyisoprenoid in vivo using a recombinant organism (plant) having these genes introduced therein.